Compare American Well Corp (AMWL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Quest Diagnostics Inc — how do they compare? American Well Corp trades at $13.01 (market cap $220.94M), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 118.6× American Well Corp's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | DGX | |
|---|---|---|
Market Cap | $220.94M | $26.21B |
Sector | Health | Health |
52-Week High | $13.58 | $238.50 |
52-Week Low | $3.78 | $173.49 |
Enterprise Value | $27.98M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.54, down 7.66% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving financial trends, with revenue declining to $249.33M in 2025 but net losses narrowing significantly to -$95.70M. Recent Q2 2026 earnings beat expectations, and news highlights strategic developments including a key executive appointment at Amazon's healthcare unit.
The outlook suggests cautious optimism as AMWL progresses toward cash-flow breakeven, supported by analyst coverage leaning Hold. Key risks include persistent revenue declines and high cash burn, though improving margins and reduced losses indicate potential for recovery if execution continues.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
